Skip to main content
. Author manuscript; available in PMC: 2019 Aug 26.
Published in final edited form as: Pharmacotherapy. 2015 Apr;35(4):412–423. doi: 10.1002/phar.1561

Table 5:

Treatment Efficacy of Biologics for Induction Therapy in Moderately to Severely Active Ulcerative Colitis21, 34,3537

Biologic Clinical Response Rate Clinical Remission Rate
Infliximab 69% 39%
Adalimumab 50% 17%
Golimumab 55% 18%
Vedolizumab 47% 17%